Citalopram for agitation in Alzheimer’s disease (CitAD): design and methods

BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer’s disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer’s disease...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Drye, Lea T., Ismail, Zahinoor, Porsteinsson, Anton P., Rosenberg, Paul B., Weintraub, Daniel, Marano, Christopher, Pelton, Gregory, Frangakis, Constantine, Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Devanand, D.P., Yesavage, Jerome, Mintzer, Jacobo E., Schneider, Lon S., Pollock, Bruce G., Lyketsos, Constantine G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3333484/
https://ncbi.nlm.nih.gov/pubmed/22301195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2011.01.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky